Case management of childhood pneumonia in developing countries
- PMID: 17468655
- PMCID: PMC2654069
- DOI: 10.1097/01.inf.0000260107.79355.7d
Case management of childhood pneumonia in developing countries
Abstract
Background: Pneumonia is a leading cause of morbidity and mortality in children worldwide. Appropriate management depends on accurate assessment of disease severity, and for the majority of children in developing countries the assessment is based on clinical signs alone. This article reviews recent evidence on clinical assessment and severity classification of pneumonia and reported results on the effectiveness of currently recommended treatments.
Methods: Potential studies for inclusion were identified by Medline (1990-2006) search. The Oxford Center for Evidence Based Medicine criteria were used to describe the methodologic quality of selected studies.
Results: In the included studies the sensitivity of current definitions of tachypnea for diagnosing radiologic pneumonia ranged from 72% to 94% with specificities between 38% and 99%; chest indrawing had reported sensitivities of between 46% and 78%. Data provide some support for the value of current clinical criteria for classifying pneumonia severity, with those meeting severe or very severe criteria being at considerably increased risk of death, hypoxemia or bacteremia. Results of randomized controlled trials report clinically defined improvement at 48 hours in at least 80% of children treated using recommended antibiotics. However, a limitation of these data may include inappropriate definitions of treatment failure.
Conclusion: Particularly with regard to severe pneumonia, issues that specifically need to be addressed are the adequacy of penicillin monotherapy, or oral amoxicillin or alternative antibiotics; the timing of introduction of high-dose trimethoprim-sulfamethoxazole in children at risk for or known to be infected by HIV and the value of pulse oximetry.
Comment in
-
A new imperative for global pneumonia control: a commentary.Pediatr Infect Dis J. 2007 May;26(5):441-2. doi: 10.1097/01.inf.0000261197.70855.1e. Pediatr Infect Dis J. 2007. PMID: 17468656 No abstract available.
-
Markers to be added to the case management of childhood pneumonia in developing countries.Pediatr Infect Dis J. 2007 Oct;26(10):969; author reply 969-70. doi: 10.1097/INF.0b013e31814689d7. Pediatr Infect Dis J. 2007. PMID: 17901813 No abstract available.
References
-
- Bryce J, Boschi-Pinto C, Shibuya K, Black R, CHERG WHO estimates of the causes of death in children. Lancet. 2005;365:1147–52. - PubMed
-
- Adegbola R, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366:144–50. - PubMed
-
- Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997;349:1191–7. - PubMed
-
- Cutts F, Zaman S, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139–46. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical